Initiated Buy X

IOVA Iovance Biotherapeutics

UBS

$17

Downgrades Overweight Neutral X

IOVA Iovance Biotherapeutics

Piper Sandler

$19 $10

Initiated Buy X

IOVA Iovance Biotherapeutics

Goldman

$12

Reiterated Overweight X

IOVA Iovance Biotherapeutics

Barclays

$40 $18

Upgrades Eq Weight Overweight X

IOVA Iovance Biotherapeutics

Wells Fargo

$11 $17

Resumed Equal Weight X

IOVA Iovance Biotherapeutics

Wells Fargo

$11

Upgrades Neutral Overweight X

IOVA Iovance Biotherapeutics

Piper Sandler

$11 $14

Downgrades Buy Neutral X

IOVA Iovance Biotherapeutics

Goldman

$20 $6

Initiated Neutral X

IOVA Iovance Biotherapeutics

Guggenheim

Resumed Equal Weight X

IOVA Iovance Biotherapeutics

Wells Fargo

$14

Resumed Outperform X

IOVA Iovance Biotherapeutics

Cowen

Upgrades Mkt Perform Mkt Outperform X

IOVA Iovance Biotherapeutics

JMP Securities

$32

Downgrades Overweight Neutral X

IOVA Iovance Biotherapeutics

Piper Sandler

$35 $18

Initiated Buy X

IOVA Iovance Biotherapeutics

Truist

$50

Initiated Buy X

IOVA Iovance Biotherapeutics

Goldman

$97

Upgrades Neutral Buy X

IOVA Iovance Biotherapeutics

H.C. Wainwright

$50

Initiated Overweight X

IOVA Iovance Biotherapeutics

Piper Jaffray

$20

Reiterated Buy X

IOVA Iovance Biotherapeutics

Chardan Capital Markets

$30 $20

Initiated Outperform X

IOVA Iovance Biotherapeutics

Robert W. Baird

Resumed Buy X

IOVA Iovance Biotherapeutics

B. Riley FBR

$24

Reiterated Buy X

IOVA Iovance Biotherapeutics

Chardan Capital Markets

Upgrades Neutral Buy X

IOVA Iovance Biotherapeutics

B. Riley FBR, Inc.

$22

Reiterated Neutral X

IOVA Iovance Biotherapeutics

B. Riley FBR, Inc.

$18.50 $22

Downgrades Buy Neutral X

IOVA Iovance Biotherapeutics

B. Riley FBR, Inc.

$18 $18.50

IOVA  Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.